1. Home
  2. IIPR vs NTLA Comparison

IIPR vs NTLA Comparison

Compare IIPR & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Industrial Properties Inc.

IIPR

Innovative Industrial Properties Inc.

N/A

Current Price

$51.60

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$12.19

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IIPR
NTLA
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2016
2016

Fundamental Metrics

Financial Performance
Metric
IIPR
NTLA
Price
$51.60
$12.19
Analyst Decision
Hold
Buy
Analyst Count
6
19
Target Price
★ $64.50
$24.00
AVG Volume (30 Days)
248.3K
★ 3.5M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
★ 14.43%
N/A
EPS Growth
N/A
★ 27.43
EPS
★ 2.39
N/A
Revenue
★ $265,955,000.00
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.98
$143.36
P/E Ratio
$22.09
★ N/A
Revenue Growth
N/A
★ 16.92
52 Week Low
$44.58
$7.95
52 Week High
$65.38
$28.24

Technical Indicators

Market Signals
Indicator
IIPR
NTLA
Relative Strength Index (RSI) 26.09 50.89
Support Level $48.51 $11.51
Resistance Level $51.68 $12.97
Average True Range (ATR) 1.02 0.61
MACD -0.36 0.01
Stochastic Oscillator 0.34 58.32

Price Performance

Historical Comparison
IIPR
NTLA

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: